Evolution of prescribing practices and outcomes in the COVID-19 pandemic in metropolitan areas.
COVID-19
metropolitan area
pandemic
prescr1ption
Journal
Le infezioni in medicina
ISSN: 2532-8689
Titre abrégé: Infez Med
Pays: Italy
ID NLM: 9613961
Informations de publication
Date de publication:
2022
2022
Historique:
received:
16
11
2021
accepted:
30
01
2022
entrez:
30
3
2022
pubmed:
31
3
2022
medline:
31
3
2022
Statut:
epublish
Résumé
We wanted to characterize the evolution of the COVID-19 pandemic in a typical metropolitan area. Data were extracted from the Detroit COVID-19 Consortium database for hospitalized COVID-19 patients treated in Southeast Michigan over the 12-month period from March 2020 to February 2021. Demographic and outcomes data were compared to CDC data. A total of 4,775 patients were enrolled during the study period. We divided the pandemic into three phases: Phase-1 (Spring Surge); Phase-2 (Summer Lull); and Phase-3 (Fall Spike). Changes in hydroxychloroquine, remdesivir, corticosteroid, antibiotic and anticoagulant use closely followed publication of landmark studies. Mortality in critically-ill patients decreased significantly from Phase-1 to Phase-3 (60.3% vs. 47.9%, Chisq p=0.0110). Monthly mortality of all hospitalized patients ranged between 14.8% - 21.5% during Phase-1 and 9.7 to 13.4% during Phase 3 (NS). The COVID-19 pandemic presented in three unique phases in Southeast Michigan. Medical systems rapidly modified treatment plans, often preceding CDC and NIH recommendations. Despite improved treatment regimens, intubation rates and mortality for hospitalized patients remained elevated. Preventive measures aimed at reducing hospitalizations for COVID-19 should be emphasized.
Identifiants
pubmed: 35350268
doi: 10.53854/liim-3001-10
pii: 1124-9390_30_1_2022_86-95
pmc: PMC8929739
doi:
Types de publication
Journal Article
Langues
eng
Pagination
86-95Informations de copyright
Copyright © 2022 InfezMed.
Déclaration de conflit d'intérêts
Conflict of interest None to declare.
Références
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 May 25;49(2):215-219
pubmed: 32391667
Cell Res. 2020 Mar;30(3):269-271
pubmed: 32020029
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
J Thromb Haemost. 2020 Apr;18(4):844-847
pubmed: 32073213
Rev Med Virol. 2021 Jan;31(1):1-10
pubmed: 32845042
Lancet. 2020 Oct 3;396(10256):959-967
pubmed: 32896292
J Thromb Haemost. 2020 May;18(5):1094-1099
pubmed: 32220112
Lancet. 2021 Feb 13;397(10274):605-612
pubmed: 33545096
N Engl J Med. 2020 Nov 5;383(19):1813-1826
pubmed: 32445440
N Engl J Med. 2020 Jun 11;382(24):2327-2336
pubmed: 32275812
Int J Antimicrob Agents. 2020 Jul;56(1):105949
pubmed: 32205204
J Am Coll Cardiol. 2020 May 12;75(18):2352-2371
pubmed: 32201335
JAMA. 2020 Jun 23;323(24):2493-2502
pubmed: 32392282